Finanzen von Eledon Pharmaceuticals Inc (ELDN)ELDNEledon Pharmaceuticals Inc

Evaluating the bottom line, Eledon Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -236.51%, provide a clear picture of how effectively ELDN converts its operational activities into shareholder value.

In the context of the broader market, ELDN competes directly with industry leaders such as NMRA and MGNX. With a market capitalization of $269.79M, it holds a significant position in the sector. When comparing efficiency, ELDN's gross margin of N/A stands against NMRA's N/A and MGNX's N/A. Such benchmarking helps identify whether Eledon Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eledon has a forward P/E ratio of 5.39, indicating potential for future profitability, but it has been experiencing significant losses with a recent net income of -39,025,000 USD for Q1 2026.